Results from the Phase I trial in humans of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a Synopsis

One of the vaccine candidates for COVID-19 at the Phase I stage is the non-replicating adenovirus type-5 (Ad5) vectored COVID-19 vaccine developed by the Beijing Institute of Biotechnology (Beijing, Read More…

Advertisements